Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacotherapy for obesity.

Lisa L Ioannides-Demos1, Joseph Proietto, John J McNeil

  • 1Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. lisa.demos@med.monash.edu.au

Drugs
|June 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Caution: very high HDL-cholesterol.

Progress in cardiovascular diseases·2026
Same author

Perceptions of end-of-life care quality among bereaved closest contacts of community-dwelling older Australians: a cross-sectional survey of the ASPREE cohort.

Research square·2026
Same author

Speech-in-Noise Ability and Longitudinal Cortical Thinning in Speech-Processing Networks.

JAMA otolaryngology-- head & neck surgery·2026
Same author

Sepsis risk associated with clonal hematopoiesis of indeterminate potential (CHIP): a secondary analysis of the ASPREE trial.

Leukemia·2026
Same author

Anti-inflammatory diet and mental health outcomes in an aging population: evidence from a preventive population-based target trial emulation.

GeroScience·2026
Same author

Polygenic Risk Identifies Older Adults Who May Benefit From Aspirin for the Primary Prevention of Ischemic Stroke.

Stroke·2026

Obesity pharmacotherapy aims for weight loss and risk reduction. Long-term options like sibutramine and orlistat show efficacy, with new treatments emerging.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Obesity Medicine

Background:

  • Pharmacotherapy for obesity management targets weight loss, maintenance, and risk reduction.
  • Historical and current agents include thyroid hormone, amphetamines, phentermine, diethylpropion, sibutramine, and orlistat.
  • These drugs act by decreasing appetite, reducing fat absorption, or increasing energy expenditure.

Purpose of the Study:

  • To review the efficacy and limitations of current pharmacotherapies for obesity management.
  • To evaluate primary and secondary endpoints used in anti-obesity drug trials.
  • To discuss challenges in clinical trial evaluation and future directions in obesity pharmacotherapy.

Main Methods:

  • Review of randomized controlled trials (RCTs) evaluating anti-obesity medications.

Related Experiment Videos

  • Analysis of short-term (<1 year) and long-term (up to 4 years) efficacy data.
  • Examination of study completion rates and potential sources of bias.

    • Main Results:

    • Most pharmacotherapies show greater weight loss than placebo in short-term RCTs.
    • Long-term efficacy is established for sibutramine (2 years) and orlistat (4 years).
    • Sibutramine and orlistat demonstrated significant weight maintenance and loss compared to placebo, though study completion rates varied.

    Conclusions:

    • Sibutramine and orlistat are currently the only approved drugs for long-term adult obesity management.
    • Low study completion rates and other biases pose challenges in evaluating anti-obesity drug efficacy.
    • Future pharmacotherapies targeting CNS pathways and peripheral signals are anticipated to significantly alter obesity treatment.